Ophthalmology

Top Story

Ozurdex implant tolerated well, with IOP spikes transient and treatable

July 26, 2017

A retrospective real-life study of patients treated with the Ozurdex dexamethasone implant for various indications showed overall good tolerance and provided useful information on risk factors for pressure elevation.

Four hundred twenty-one eyes of 361 patients were analyzed in the SAFODEX study. They received 1,000 injections for macular edema secondary to retinal vein occlusion, diabetic macular edema, postsurgical macular edema, uveitis and other etiologies. Pre-existing ocular hypertension or glaucoma was present in 14% of eyes. Re-treatment was required in 58% of eyes, and one-third of the patients received at least three Ozurdex implants (Allergan).

4D Molecular Therapeutics teams with Foundation Fighting Blindness to develop gene therapies

July 26, 2017
4D Molecular Therapeutics announced a partnership with Foundation Fighting Blindness to develop intravitreal gene therapeutics for patients with inherited retinal…

ASCRS, ASOA representatives meet with Congress members at annual fly-in

July 26, 2017
About 50 physicians and ophthalmic administrators representing the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic…

Allegro Ophthalmics receives $10.7 million in private financing

July 26, 2017
Allegro Ophthalmics announced it has secured $10.7 million in a private round of equity financing. The additional capital will allow the company to complete several…

New definition of dry eye disease recognizes its multifactorial nature

July 25, 2017
The TFOS DEWS II membership acknowledged the need to recognize the multifactorial nature of dry eye disease, which has led to a refined definition of the disease…
More Headlines »
Original Article

Prevalence, Incidence, and Risk Factors for the Development of Glaucoma in Patients With Aniridia

Journal of Pediatric Ophthalmology and Strabismus, July/August 2017, Volume 54 Issue 4
To assess the prevalence, incidence, and risk factors for the development of glaucoma in patients with aniridia…
More »
CME

Eye on an Enigma: New Mechanisms of Action in the Medical Management of Glaucoma

This activity is supported by an educational grant from Bausch + Lomb.

Glaucoma is currently the second leading cause of blindness throughout the world. The goal of glaucoma treatment is to…
More »
Resource Centers
Video
Meeting News

VIDEO: Data analytics important for private ophthalmology practices

June 25, 2017
More »
Advertisement
Advertisement